PPL 36.51 PPL Corp $PPL Hit a 52 week high of 36.51

New Post Public Reply Private Reply Replies (0) Message Board
DennyT
PPL 36.51 PPL Corp $PPL Hit a 52 week high of 36.51 Currently at 36.51 +0.52 +1.44% With a day low of 35.91 and a total volume of 4,160,500.

PPL PPL Corp Recent Headline News

Northeast Utilities (NU) Misses on Q3 Earnings & Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 10:30AM CST
In the third quarter of 2014, Northeast Utilities' (NU) earnings per share and revenues missed the Zacks Consensus Estimate.
SE: 39.66 (+0.58), PPL: 36.51 (+0.52), SEP: 56.37 (-0.63), NU: 50.70 (+1.20)

PPL's Presentation to be Webcast from Edison Electric Institute's Annual Financial Conference
PR Newswire - Thu Nov 06, 1:28PM CST
PPL Corporation (NYSE: PPL) Chairman, President and Chief Executive Officer William H. Spence will outline the company's strategy and general business outlook to investors and financial analysts at the Edison Electric Institute's 49th annual financial conference in Dallas, Texas, on Thursday, Nov. 13, at 10:30 a.m. Central time.
PPL: 36.51 (+0.52)

Westar Energy Beats Q3 Earnings on Higher Electric Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 10:00AM CST
Westar Energy's (WR) earnings and revenues in the third quarter 2014 were ahead of the Zacks Consensus Estimate.
WR: 39.09 (+0.83), FE: 37.25 (+0.61), PPL: 36.51 (+0.52), ALE: 52.25 (+0.44)

SmarTrend Watching for Potential Pullback in Shares of PPL After 4.15% Gain
Comtex SmarTrend(R) - Wed Nov 05, 4:01PM CST
PPL (NYSE PL) traded in a range yesterday that spanned from a low of $35.23 to a high of $36.42. Yesterday, the shares gained 4.1%, which took the trading range above the 3-day high of $35.42 on volume of 11.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
PPL: 36.51 (+0.52)

After Yesterday's Rally of 4.15% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Nov 05, 4:00PM CST
PPL (NYSE PL) traded in a range yesterday that spanned from a low of $35.23 to a high of $36.42. Yesterday, the shares gained 4.1%, which took the trading range above the 3-day high of $35.42 on volume of 11.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
PPL: 36.51 (+0.52)

One Reason NRG Energy (NRG) Stock Is Climbing Today
at The Street - Wed Nov 05, 1:55PM CST
NRG Energy (NRG) stock is rising after benchmark U.S. crude prices gained, and the company reported a rise in its 2014 third quarter earnings results.
NEE: 104.73 (+0.78), FE: 37.25 (+0.61), PPL: 36.51 (+0.52), NRG: 33.72 (+1.09)

NRG Energy (NRG) Misses Q3 Earnings Estimates, Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 1:18PM CST
In the third quarter of 2014, NRG Energy, Inc.'s (NRG) earnings per share missed the Zacks Consensus Estimate while revenues beat the same.
EXC: 37.77 (+0.33), PPL: 36.51 (+0.52), NYLD: 48.48 (-0.70), NRG: 33.72 (+1.09)

PPL cutting 450 jobs ahead of plant spinoff
AP - Wed Nov 05, 9:49AM CST
ALLENTOWN, Pa. (AP) — A Pennsylvania utility says it's eliminating 450 jobs as part of cost-cutting stemming from a planned spinoff of its competitive generation business.
PPL: 36.51 (+0.52)

PPL Corporation (PPL) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Tue Nov 04, 11:37AM CST
The following PPL Corporation (PPL) conference call took place on November 4, 2014, 08:30 AM ET. This is a transcript of that earnings call:
PPL: 36.51 (+0.52)

PPL Corp. (PPL) Beats Q3 Earnings Estimates, Ups Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 9:50AM CST
In the third quarter of 2014, PPL Corporation's (PPL) earnings per share and revenues surpassed the Zacks Consensus Estimate.
EXC: 37.77 (+0.33), PEG: 41.10 (+0.38), PPL: 36.51 (+0.52), EIX: 62.38 (+0.39)

Electric Utilities Stocks Technical Report - American Electric Power, PPL Corp., Edison Intl., Centrais Eletricas Brasileiras, and Great Plains Energy
PR Newswire - Tue Nov 04, 8:30AM CST
Investor-Edge has initiated coverage on the following equities: American Electric Power Company Inc. (NYSE: AEP), PPL Corporation (NYSE: PPL), Edison International (NYSE: EIX), Centrais Eletricas Brasileiras S.A. (NYSE: EBR), and Great Plains Energy Inc. (NYSE: GXP). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, November 03, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,366.24, down 0.14% and the NASDAQ Composite closed at 4,638.91, up 0.18%. The S&P 500 finished the session 0.01% lower at 2,017.81. During the trading session, seven out of ten sectors finished on a higher note. The S&P 500 Utilities Sector Index ended the day at 232.53, up 0.69%, with the index gaining 10.59% in the previous three months. Register for your complimentary reports on these five stocks at:
AEP: 58.32 (+0.45), GXP: 27.00 (+0.08), PPL: 36.51 (+0.52), EBR: 2.32 (+0.04), EIX: 62.38 (+0.39)

Quarterly Earnings, Customer Alert Warning, Project Updates, and Earnings Schedules - Research Reports on Exelon, Duke Energy, Dominion, PPL and Edison
PR Newswire - Tue Nov 04, 7:30AM CST
Today, Analysts Review released its research reports regarding Exelon Corporation (NYSE: EXC), Duke Energy Corporation (NYSE: DUK), Dominion Resources, Inc. (NYSE: D), PPL Corporation (NYSE: PPL) and Edison International (NYSE: EIX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7664-100free.
D: 73.89 (+0.81), DUK: 82.08 (+0.91), EXC: 37.77 (+0.33), PPL: 36.51 (+0.52), EIX: 62.38 (+0.39)

PPL beats 3Q profit forecasts
Automated Insights - Tue Nov 04, 6:21AM CST
ALLENTOWN, Pa. (AP) _ PPL Corp. (PPL) on Tuesday reported earnings of $497 million in its third quarter.
PPL: 36.51 (+0.52)

PPL Corporation Reports Third-Quarter Earnings
PR Newswire - Tue Nov 04, 5:57AM CST
PPL Corporation (NYSE: PPL) announced on Tuesday (11/4) third-quarter 2014 reported earnings of $497 million, or $0.74 per share, an increase from $410 million, or $0.62 per share, a year ago. For the first nine months of 2014, PPL's reported earnings were $1.04 billion, or $1.57 per share, compared with $1.23 billion, or $1.90 per share, in the first nine months of 2013.
PPL: 36.51 (+0.52)

What to Expect When PPL Corp. (PPL) Reports Third-Quarter Earnings Tuesday
at The Street - Mon Nov 03, 11:06AM CST
PPL Corp. (PPL) is gaining Monday ahead of the electric utility company's earnings report on Tuesday morning.
PPL: 36.51 (+0.52)

Will PPL Corporation (PPL) Miss Q3 Earnings Expectations? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 5:20PM CDT
PPL Corporation (PPL) is scheduled to report third-quarter 2014 results before the opening bell on Nov 4.
DUK: 82.08 (+0.91), PPL: 36.51 (+0.52), ED: 63.57 (+0.32), ALE: 52.25 (+0.44)

PPL Corporation to Conduct Webcast on Third-Quarter 2014 Results
PR Newswire - Thu Oct 23, 1:28PM CDT
PPL Corporation (NYSE: PPL) will release consolidated third-quarter 2014 earnings results before the stock market opens on Tuesday, November 4.
PPL: 36.51 (+0.52)

Watch for PPL to Potentially Pullback After Gaining 1.24% Yesterday
Comtex SmarTrend(R) - Wed Oct 22, 4:21PM CDT
PPL (NYSE PL) traded in a range yesterday that spanned from a low of $33.97 to a high of $34.51. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $34.08 on volume of 4.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
PPL: 36.51 (+0.52)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 397

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
BAIC FOTON Eyes African Market with Strategic Moves

Updated Category News Views 149

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

Continue Reading
RYBREVANT's Promising Results in HNSCC Treatment

Updated Category News Views 205

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 606

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Updated Category News Views 288

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Continue Reading
Gildan Activewear Faces Legal Battle Over Alleged Fraud

Updated Category News Views 196

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Continue Reading
Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 245

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 258

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 223

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 322

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading

Top 5 Most Recently Viewed Articles

Care Synergy and RCC Medical Equipment Launch New Partnership

Updated Category News Views 320

Care Synergy and RCC Medical Equipment Form Joint Venture In an exciting development for healthcare services, Care Synergy and RCC Medical Equipment Co. have announced their plans to create a strategic joint venture aimed at improving healthcare delivery in the Colorado Front Range region. This partnership will leverage the strengths of both organizations to provide...

Continue Reading
Revitalizing China's Tourism with High-Tech Cultural Experiences

Updated Category News Views 217

Revitalizing China's Tourism Through High-Tech Cultural Experiences China's tourism industry is undergoing an exciting transformation, fueled by the innovative use of advanced technology paired with its rich cultural heritage. A remarkable example is in Chongqing Municipality, where the city's skyline has become a vibrant showcase of cultural stories, highlighted by...

Continue Reading
Intriguing Insights into United States Steel Options Trades

Updated Category News Views 111

Analyzing Unusual Options Activity in United States Steel Recently, there's been notable market activity where investors with deep pockets are taking a more bearish stance on United States Steel (X). This trend is definitely something for retail traders to pay attention to, especially when navigating the complexities of the stock market. Today's options history unveiled...

Continue Reading
Mesoblast's Operational Highlights and Financial Insights Unveiled

Updated Category News Views 185

Mesoblast Limited's Webcast for Financial Results On a recent occasion, Mesoblast Limited (NASDAQ: MESO; ASX: MSB), a pioneer in allogeneic cellular medicine for inflammatory diseases, announced a webcast to delve into their operational achievements and financial metrics for the half year concluding December 31, 2024. Details of the Webcast Event The engaging webcast is...

Continue Reading
Investors of DXC Technology Prepare for Class Action Lawsuit

Updated Category News Views 77

Investors of DXC Technology Company Take Action In recent months, investors who purchased common stock from DXC Technology Company (NYSE: DXC) have been given a significant opportunity to participate in a class action lawsuit. This situation arises from allegations of securities fraud that are said to have affected many individuals who bought shares during specific key...

Continue Reading